Stratos Wealth Partners’s ImmunityBio IBRX Stock Holding History

Stratos Wealth Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-34,050	Closed	-$171K	–	1425
2023 Q4	$171K	Buy	+34,050	New	+$107K	﹤0.01%	1292

Other funds holding IBRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stratos Wealth Partners's IBRX Position: Q1 2024 in Review

Stratos Wealth Partners sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 34,050 shares — an estimated $171K sold.

Stratos Wealth Partners first reported a position in IBRX in Q4 2023 and held it in 1 quarter. The position peaked at $171K in Q4 2023. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

Stratos Wealth Partners reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
Stratos Wealth Partners sold 34,050 ImmunityBio shares in Q1 2024, an estimated $171K.
Stratos Wealth Partners first reported a position in ImmunityBio in Q4 2023 and held it in 1 quarter.
Stratos Wealth Partners's ImmunityBio position peaked at $171K in Q4 2023.
165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Stratos Wealth Partners's 13F filing for Q1 2024, filed 16 Apr 2024.